AmnioChor was founded by the integration of science, medicine, and engineering and is a biotech company based in plurinatal stem cell technology. The Company has identified a source and method of acquiring and preserving human stem cells. AmnioChor's stem cells, Mesenchymal in composition, will allow a tremendous expansion of the private stem cell storage industry and stem cell based therapies. The Mesenchymal stem cells that reside in the amnion, are readily available in pristine quality at childbirth. AmnioChor has developed the technology to capture and cryopreserve the placental tissue, and is building a new tissue bank. The OMNIBANK will comprise a fee based personal storage, and a separate community component based on tissue donations. AmnioChor's long term vision is based on the significant cached value of their cells and what they will provide to the burgeoning regenerative medicine and cellular therapy industries, the future of healthcare.